Correction to: Prevalence and risk factors for hypoparathyroidism following total thyroidectomy in Spain: a multicentric and nation-wide retrospective analysis
Juan J. Díez(Instituto Cajal), Pedro Iglesias(Hospital Universitario Puerta de Hierro Majadahonda), Cecilia Sánchez-Ragnarsson(Hospital Universitario Central de Asturias), Sergio Donnay(Hospital Universitario Fundación Alcorcón), Juan C. Galofré(Instituto de Salud Pública de Navarra), Ana Megía(Institut de Recerca Biomèdica Catalunya Sud), Concepción Blanco Carrera(Hospital Universitario Príncipe de Asturias), Carles Zafón(Vall d'Hebron Hospital Universitari), Begoña Pérez Corral(Complejo Asistencial Universitario de Palencia), Laura Manjón(Hospital Universitario Central de Asturias), Emma Anda(Complejo Hospitalario de Navarra), Orosia Bandrés(Hospital Royo Villanova), Cristina Álvarez‐Escolá(Hospital Universitario La Paz), Gloria Baena‐Nieto(Hospital Jerez Puerta del Sur), Ana R. Romero-Lluch(Hospital Universitario Virgen del Rocío), María Picallo(Hospital General Universitario Gregorio Marañón), Manel Sahún de la Vega(Hospital de Sant Joan Despí Moisès Broggi), Laura Oleaga(Hospital de Basurto), Marcel Sambo(Hospital General Universitario Gregorio Marañón), Piedad Santiago Fernández(Complejo Hospitalario de Jaén), Elena Navarro González(Universidad de Granada), Eva Sanz(Vall d'Hebron Hospital Universitari), Miguel Paja(Hospital de Basurto), José Carlos Fernández García(Hospital Clínico Universitario Virgen de la Victoria), Julia Sastre(Complejo Hospitalario Universitario de Toledo), Beatriz Lecumberri(Hospital Universitario La Paz)
Cited by 0
Related Papers
Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement
|Nature Reviews Endocrinology|2018|346
Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients
|Endocrine Related Cancer|2015|204
From pseudohypoparathyroidism to inactivating PTH/PTHrP signalling disorder (iPPSD), a novel classification proposed by the EuroPHP network
|European Journal of Endocrinology|2016|174
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
|Annals of Oncology|2015|157
GLUT1 deficiency and other glucose transporter diseases
|European Journal of Endocrinology|2004|145